GlobeNewsWire
08 Apr 2026, 13:07 UTC · 32w ago
Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation
Impact · against what's priced in
Mesoblast's R&D Day provides multiple positive catalysts, most notably the accelerated regulatory path for Ryoncil in DMD and a concrete plan to double net revenues. These developments, combined with the Mayo Clinic CAR technology acquisition and upcoming Phase 3 CLBP enrollment closure, suggest a significant increase in both near-term commercial momentum and long-term pipeline value.
- MSB+0.70
No priced-in read yet





